Becton, Dickinson and Company $BDX Stock Holdings Boosted by WCG Wealth Advisors LLC

WCG Wealth Advisors LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 142.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 24,340 shares of the medical instruments supplier’s stock after buying an additional 14,283 shares during the period. WCG Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $4,724,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 71.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after purchasing an additional 34,437 shares during the last quarter. Assetmark Inc. boosted its position in shares of Becton, Dickinson and Company by 49.5% in the 3rd quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after purchasing an additional 74,795 shares during the period. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after purchasing an additional 147,041 shares during the period. Finally, Skba Capital Management LLC increased its stake in Becton, Dickinson and Company by 1,619.9% in the 3rd quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock worth $10,765,000 after purchasing an additional 54,170 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 2,913 shares of company stock valued at $426,806. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 2.6%

BDX stock opened at $149.47 on Friday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a market cap of $41.18 billion, a PE ratio of 37.84, a price-to-earnings-growth ratio of 10.31 and a beta of 0.22. The business’s 50-day simple moving average is $150.86 and its 200 day simple moving average is $175.71. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Analyst Ratings Changes

A number of research firms have commented on BDX. Barclays upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Evercore upped their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Stifel Nicolaus reduced their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Finally, Argus lowered their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $183.64.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.